Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study

被引：3

作者：

Shah, Nirav N. ^{[1
]}

Zinzani, Pier Luigi ^{[2
]}

Wang, Michael L. ^{[3
]}

Nasta, Sunita D. ^{[4
]}

Lech-Maranda, Ewa ^{[5
]}

Ogawa, Yoshiaki ^{[6
]}

Fakhri, Bita ^{[7
]}

Kuss, Bryone ^{[8
,9
]}

Miyashita, Kaname ^{[10
]}

Patel, Krish ^{[11
]}

Coombs, Catherine C. ^{[12
]}

Ma, Shuo ^{[13
]}

Patel, Manish ^{[14
]}

Barve, Minal A. ^{[15
]}

Tessoulin, Benoit ^{[16
,17
]}

Stathis, Anastasios ^{[18
]}

Kim, Won Seog ^{[19
]}

Ennishi, Daisuke

Hashimoto, Daigo ^{[20
,21
]}

Kojima, Kensuke ^{[22
]}

Zelenetz, Andrew D. ^{[23
]}

Cohen, Jonathon B. ^{[24
]}

Vose, Julie M. ^{[25
]}

Maddocks, Kami J. ^{[26
]}

Munir, Talha ^{[27
]}

Sun, Fangfang ^{[28
]}

Bian, Faith ^{[28
]}

Tsai, Donald E. ^{[29
]}

Abada, Paolo ^{[29
]}

Cheah, Chan Y. ^{[30
,31
]}

机构：

[1] Med Coll Wisconsin, Milwaukee, WI USA

[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[3] Texas MD Anderson Canc Ctr, Houston, TX USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[5] Inst Hematol & Transfus Med, Warsaw, Poland

[6] Tokai Univ, Sch Med, Hiratsuka, Kanagawa, Japan

[7] Stanford Univ, Sch Med, Stanford, CA USA

[8] Flinders Med Ctr, Bedford Pk, Australia

[9] Flinders Univ S Australia, Bedford Pk, Australia

[10] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan

[11] Swedish Canc Inst, Seattle, WA USA

[12] Univ Calif Irvine, Irvine, CA USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[14] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[15] Mary Crowley Canc Res, Dallas, TX USA

[16] Nantes Univ, Sch Med, Nantes, France

[17] Univ Hosp Nantes, Nantes, France

[18] Oncol Inst Southern Switzerland, Bellinzona, Switzerland

[19] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[20] Okayama Univ Hosp, Okayama, Japan

[21] Hokkaido Univ Hosp, Sapporo, Japan

[22] Kochi Med Sch Hosp, Nankoku, Japan

[23] Mem Sloan Kettering Canc Ctr, New York, NY USA

[24] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[25] Univ Nebraska Med Ctr, Omaha, NE USA

[26] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[27] St James Univ Hosp, Dept Haematol, Leeds, England

[28] Eli Lilly & Co, Indianapolis, IN USA

[29] Loxo Lilly, Indianapolis, IN USA

[30] Linear Clin Res, Perth, Australia

[31] Sir Charles Gairdner Hosp, Perth, Australia

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-181309

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[21] Pirtobrutinib, a Next-Generation, Highly Selective, Noncovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[22] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
[23] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
[24] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Gerson, James N.
Flinn, Ian W.
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna M.
Patel, Krish
Woyach, Jennifer A.
Lamanna, Nicole
Wang, Yucai
Tam, Constantine S.
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew D.
Jain, Preetesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo B.
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BLOOD, 2022, 140 : 9368 - 9372
[25] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
Lewis, David John
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutzu, Koji
Gerson, James N.
Flinn, Ian
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna
Patel, Krish
Woyach, Jennifer
Lamanna, Nicole
Wang, Yucai
Tam, Constantine
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew
Jain, Preteesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109
[26] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor Therapy
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John
Shah, Nirav N.
Ujjani, Chaitra
Fahkri, Bita
Coombs, Catherine C.
Flinn, Ian
Patel, Manisha R.
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhoades, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Ruppert, Amy S.
Li, Jian
Jurczak, Wojciech
Wierda, William G.
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119
[27] Efficacy of Pirtobrutinib in Relapsed/ Refractory CLL and Richter Transformation: Additional Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 16 - 16
[28] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo B.
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BLOOD, 2022, 140 : 2316 - 2320
[29] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
Eyre, Toby
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Woyach, Jennifer
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abedel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 37 - 38
[30] Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults
De, Surya K.
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (30) : 4757 - 4762

← 1 2 3 4 5 →